

2025 臺中榮民總醫院院慶國際醫學研討會

TCVGH International Medical Conference

AI in Medicine

Future of Healthcare by AI



	Name	蔡政憲
	Country	Taiwan
	Official Title	董事長
	Department	外泌體全球研發代工
	Institute	<input type="checkbox"/> 訊聯細胞智藥股份有限公司
	Telephone / Fax	
	E-Mail	
	Mailing Address	
Education Background	B.S. Chemical Engineering National Taiwan University, Taipei, Taiwan <input type="checkbox"/> Ph.D. Chemical Engineering & Material Science University of Minnesota, Minneapolis, Minnesota	
Professional Career	<input type="checkbox"/> 2003~2005 Chairman, Asia Pacific Cord Blood Bank Consortium (APCBBC) <input type="checkbox"/> 2012~2013 Regional Vice President, International Society for Cellular Therapy (ISCT) <input type="checkbox"/> 2013~2015 Steering committee, ISCT <input type="checkbox"/> 2023~Convener, Exosomes Focus Group of Taiwan Bio Industry Organization <input type="checkbox"/> 2023~ Steering Committee, Taiwan Alliance for Extracellular Vesicles (TAEV) <input type="checkbox"/> 2023~ President, Precision Medicine Industry Association of Taiwan (PMIA) <input type="checkbox"/> 2024~ Vice President, Taiwan Bio Industry Organization	

Speech Title	Applications of AI and Exosome Technology in the Clinical Practice and Research of Traditional Chinese Medicine
Abstract(200 words) :	<p>Artificial intelligence (AI) is profoundly reshaping the biopharmaceutical industry, leading innovation in new drug research and development. Within this trend, exosomes, with their immunomodulatory, anti-inflammatory, and tissue regenerative capabilities, have become a key platform for regenerative medicine due to their precise intercellular signaling, opening new opportunities for the treatment of multi-system diseases. Current clinical applications focus on reproductive medicine (such as ovarian function regulation, endometrial regeneration, and intimate mucosal repair), and are expanding into areas such as orthopedic degeneration (such as osteoarthritis) and skin regeneration (such as deep wound healing).</p> <p>AI applications have achieved substantial breakthroughs. For example, the first AI-designed drug from Google DeepMind's Isomorphic Labs has entered human trials, marking a significant advancement in AI's molecular mechanism exploration. In response to this development, Bionet Group has been continuously innovating in technology since 2008 and launched the "AI Foundry" and "Exosome R&D Outsourcing" projects in 2024. Combined with NRICM (Taiwan Chingguan Yihau), they are validating the dual-action "AI × Exosome" technology, which can precisely regulate molecular pathways and significantly enhance the efficacy of combined therapies. The Group is further leveraging the unique exosome delivery system to expand into regenerative medicine and medical aesthetics applications, including skin, hair follicle regeneration, and bone rehabilitation. Through deep AI integration, it is accelerating drug development, medical aesthetics manufacturing, and Chinese herbal medicine research, driving the industry towards a new stage of efficiency and precision.</p>